Metrics to compare | CRDL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCRDLPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.8x | −2.4x | −0.2x | |
PEG Ratio | −0.16 | 0.00 | 0.00 | |
Price/Book | 6.9x | 0.8x | 2.6x | |
Price / LTM Sales | - | 0.6x | 2.8x | |
Upside (Analyst Target) | 396.5% | 95.1% | 60.9% | |
Fair Value Upside | Unlock | 29.4% | 9.5% | Unlock |
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.